Research of Small-Molecule Therapeutics in Transplantation and Tolerance
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cell Biology and Pathology".
Deadline for manuscript submissions: 30 April 2024 | Viewed by 903
Special Issue Editor
Special Issue Information
Dear Colleagues,
Organ transplantation is the best curative treatment for patients with end-stage organ disease. An unavoidable complication leading to early allograft dysfunction is mediated primarily by ischemia-reperfusion injury (IRI). This peri-transplant clinical condition is characterized by interrelated phases involving donor-tissue ischemic necrosis and recipient reperfusion, which introduces the innate-adaptive immune interface that promotes pro- and anti-inflammatory responses. As the consequences of I/R injury remain vast, understanding the mechanistic factors leading to I/R injury remains a top priority. Determining the peak induction potential of the signaling networks that attenuate antioxidant, detoxification, and homeostatic functions may be the key to understanding why specific therapeutic strategies fail to advance through clinical trials.
In the past year, small-molecule therapeutics, comprised of RNA, protein, and/or drug-based molecules, have achieved impressive results regulating gene expression networks involved in pro- and anti-inflammatory responses to organ transplantation injury. They have been shown to significantly increase the capacity to prevent organ rejection by reducing oxidative stress and inflammation, modulating the immune response, and stimulating the production of protective enzymes that promote tissue repair. The aim of this Special Issue is to illustrate how these small molecules hold the potential to improve the survival of patients undergoing solid organ transplantation.
Dr. Kenneth J. Dery
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- organ transplantation
- oxidative stress
- ischemia-reperfusion injury
- short-activating RNA
- small-molecule therapeutics
- early allograft dysfunction
- morpholinos
